ProfileGDS5678 / 1437489_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 95% 93% 95% 93% 92% 94% 93% 92% 93% 93% 92% 93% 92% 93% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.5503195
GSM967853U87-EV human glioblastoma xenograft - Control 28.0049593
GSM967854U87-EV human glioblastoma xenograft - Control 38.4568595
GSM967855U87-EV human glioblastoma xenograft - Control 48.0380793
GSM967856U87-EV human glioblastoma xenograft - Control 57.7650392
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.9792894
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.7309293
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.4914792
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.8380593
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.8569793
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.680692
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.0244293
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.6777292
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.7913793